Final-Program-ATS-2023-AP.vp

92

SUNDAY • MAY 21

P1064 Lactobacillus Rhamnosus Supernatant Insufficient in Limiting the Adverse Effects of Bleomycin Induced Lung Fibrosis/ A. Lancaster, Nashville, TN P1065 The Effect of Quercetin on Human Lung Fibroblasts and Regulation of Collagen Production/ Z. Wiggins, Nashville, TN P1066 A Biomarker of Club Cell Secretory Protein 16 Degraded by Human Neutrophil Elastase (CC16-HNE) Is Elevated in Patients With Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease/ H.W. Breisnes, Herlev, Denmark P1067 An Unbiased Proteomic Screen of Bronchoalveolar Lavage Fluid in the Sftpc Mouse Identifies Potential Biomarkers for Idiopathic Pulmonary Fibrosis/ K. Chavez, Philadelphia, PA P1068 CXCL1 Is Highly Expressed in Secretory Cells and Correlates With Poor Outcomes in Patients With Idiopathic Pulmonary Fibrosis/ H. Bahudhanapati, Pittsburgh, PA P1069 Sodium Alginate Hydrogels as an Alternate to Agarose for Lung Inflation/ J.A. Mereness, Rochester, NY P1070 Impact of Enzymatic Digestion on Single Cell Suspension Yield From Human Lungs/ A. Bondonese, Pittsburgh, PA P1071 Soft Microenvironment Engenders ‘Afibrogenic’ Phenotype in Pulmonary Fibroblasts/ A. Gunatilaka, Parkville, Australia P1072 Micro-Computed Tomography Visualization and Quantitation of the Aging Pulmonary Microvascular Tree in Chronic Lung Disease/ B. Schneider, Denver, CO P1073 The Utility of Transbronchial Cryobiopsy as Precision Medicine for Interstitial Pneumonia/ H. Kitamura, Yokohama, Japan P1074 Novel Echogenic Liposomal Carriers Loaded With Tissue Plasminogen Activator and Urokinase Plasminogen Activator for Preclinical Studies/ M. Ranjpour, Tyler, TX P1075 Plasminogen Activators Encapsulated Into Microfiber Carriers to Deliver and Support Sustainable Plasminogen Activation/ M. Ranjpour, Tyler, TX P1076 Fresh Biospecimen Distribution to Enhance Pulmonary Research Via Human Tissue Biobanking/ S.D. Stacey, Columbus, OH P1077 Rapid Low-ischemic Time Lung Explant Tissue Collection at the University of California San Diego/ K. Afshar, La Jolla, CA P1078 Inhalational Delivery of MRI-1867 (Zevaquenabant) as a Novel Therapeutic Modality in Pulmonary Fibrosis/ A. Basu, Rockville, MD

P1049 Assessing Challenges and Opportunities for Biomarker, Device, and Pre-clinical Drug Development/Commercialization in the Pulmonary Arena/ L. Hecker, Atlanta, GA P1050 Mtor Signalling and More in Dipnech/ M. O’Callaghan, Dublin, Ireland P1051 Programmed Cell Death Protein 1 (PD-1) Is an Effective Inducer of IL-6 Expression in Sarcoidosis CD4+ T Cells/ O.S. Chioma, Nashville, TN P1052 Preclinical Profile of PRS-220, a Novel Inhaled Inhibitor of CTGF/CCN2 in Clinical Development for Idiopathic Pulmonary Fibrosis/ V. Neiens, Hallbergmoos, Germany P1053 Novel Small Molecule Rock Inhibitor GNS-3595 Attenuates Idiopathic Pulmonary Fibrosis Progression in Preclinical Models/ S. Hwang, Billerica, MA P1054 The Anti-fibrotic Effect OFGB0139, a Small Molecule Galectin-3 Inhibitor, in Precision Cut Lung Slices From Idiopathic Pulmonary Fibrosis Tissue/ A.C. Mackinnon, Edinburgh, United Kingdom P1055 Anti-fibrotic Potential of a Novel Long-acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Idiopathic Pulmonary Fibrosis/ J.A. Kim, Hwaseong-si, Korea, Republic of P1056 Pathogenic Role of Extracellular Heat Shock Protein 90 a (HSP90 a ) in Interstitial Lung Diseases Through Macrophages Programming/ T. Isshiki, Hamilton, Canada P1057 Analysis of the Anti-fibrotic Potential of JAK Inhibitors in a Bleomycin-induced Pulmonary Fibrosis Model/ K. Murakami, Tokushima, Japan P1058 Chemical Activation of Protein Phosphatase 2A Counters Bleomycin-induced Fibrosis in Mice/ M. Pillai, Brooklyn, NY P1059 Structure Based Discovery and Anti-fibrotic Activity of Novel Antagonists of Lysophosphatidic Acid Receptor 1 (LPAR1)/ C. Tan, South San Francisco, CA P1060 Type VI Collagen Formation Is Induced in a Scar-in-a-Jar Fibroblast Model Stimulated With a Combination of TGF-ß and PDGF/ F.B. Simoes, Herlev, Denmark P1061 Evaluation of Rodent PRO-C6, a Biomarker of Type VI Collagen Formation, in a Bleomycin Induced IPF Mouse Model/ M. Skarsfeldt, Herlev, Denmark P1062 Inhaled Alpha1 Adrenoreceptor Antagonism Does Not Affect Experimentally Induced Lung Fibrosis in Animal Models/ A. Ghincea, New Haven, CT P1063 Inhaled Alpha2 Adrenoreceptor Agonism Does Not Affect Experimentally Induced Lung Fibrosis in Animal Models/ J. Mcgovern, New Haven, CT

ATS 2023 • Washington, DC